Eman Ms Muhammad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eman Ms Muhammad has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Edwin K. Jackson
Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine
7 shared publications Stevan P. Tofovic
Medicine
3 shared publications- Stevan P. Tofovic
Pharmacology and Chemical Biology; and
3 shared publications Mona F Melhem
2 shared publicationsMona Melhem
Department of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
2 shared publicationsSheldon I. Bastacky
Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA
2 shared publications
Latest Publications
- Open Access
- 1 December 2020
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 13, 1005-1013
Assessment of the Effect of Metabolic Syndrome on the Autophagy Marker LC3 in Psoriasis Vulgaris Patients: A Cross-Sectional Study
Purpose: Psoriasis vulgaris, one of the most prevalent chronic inflammatory skin diseases, is associated with metabolic syndrome (MetS). Autophagy, an intracellular degradation system is essential for cell survival and differentiation, and its dysfunction may contribute to metabolic diseases. A cross-sectional study was conducted on 38 psoriasis vulgaris patients and 16 healthy control subjects to 1) Assess immunohistochemical (IHC) expression of microtubule-associated protein light chain 3 (LC3); 2) Evaluate the relationship between Psoriasis Area Severity Index (PASI) score, and LC3 expression. Patients and Methods: PASI score was evaluated for all psoriasis patients. Lipid profile, blood sugar, and CRP were done for all patients and controls. A punch biopsy was taken from lesional and perilesional skin of psoriasis patients and normal skin of the controls. Tissue sections were prepared. IHC LC3 staining was done and evaluated. Results: LC3 was nearly absent, in the epidermis of the lesional skin of psoriasis while it was strong among control (p=0.001). LC3 expression in the lesional skin of psoriasis vulgaris was lower than its expression in perilesional (p=0.001). However, LC3 expression was not significantly changed with PASI or the presence/absence of MetS. Conclusion: A potential link between psoriasis vulgaris and autophagy as assessed by LC3 could be present. LC3 was down-regulated in psoriasis lesions than in normal skin. However, its expression did not change with PASI or MetS. An autophagy enhancer might be used as a possible therapeutic target in psoriasis vulgaris patients.
- 1 December 2020
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 13, 1005-1013
Open AccessAssessment of the Effect of Metabolic Syndrome on the Autophagy Marker LC3 in Psoriasis Vulgaris Patients: A Cross-Sectional Study
Purpose: Psoriasis vulgaris, one of the most prevalent chronic inflammatory skin diseases, is associated with metabolic syndrome (MetS). Autophagy, an intracellular degradation system is essential for cell survival and differentiation, and its dysfunction may contribute to metabolic diseases. A cross-sectional study was conducted on 38 psoriasis vulgaris patients and 16 healthy control subjects to 1) Assess immunohistochemical (IHC) expression of microtubule-associated protein light chain 3 (LC3); 2) Evaluate the relationship between Psoriasis Area Severity Index (PASI) score, and LC3 expression. Patients and Methods: PASI score was evaluated for all psoriasis patients. Lipid profile, blood sugar, and CRP were done for all patients and controls. A punch biopsy was taken from lesional and perilesional skin of psoriasis patients and normal skin of the controls. Tissue sections were prepared. IHC LC3 staining was done and evaluated. Results: LC3 was nearly absent, in the epidermis of the lesional skin of psoriasis while it was strong among control (p=0.001). LC3 expression in the lesional skin of psoriasis vulgaris was lower than its expression in perilesional (p=0.001). However, LC3 expression was not significantly changed with PASI or the presence/absence of MetS. Conclusion: A potential link between psoriasis vulgaris and autophagy as assessed by LC3 could be present. LC3 was down-regulated in psoriasis lesions than in normal skin. However, its expression did not change with PASI or MetS. An autophagy enhancer might be used as a possible therapeutic target in psoriasis vulgaris patients.
- 1 March 2019
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 73 (3) , 165-177
2-Methoxyestradiol Attenuates Angiotensin II-Induced Hypertension, Cardiovascular Remodeling, and Renal Injury
Estradiol may antagonize the adverse cardiovascular effects of angiotensin II (Ang II). We investigated the effects of 2-methoxyestradiol (2-ME), a nonestrogenic estradiol metabolite, on Ang II-induced cardiovascular and renal injury in male rats. First, we determined the effects of 2-ME on Ang II-induced acute changes in blood pressure, renal hemodynamics, and excretory function. Next, we investigated the effects of 2-ME and 2-hydroxyestardiol (2-HE) on hypertension and cardiovascular and renal injury induced by chronic infusion of Ang II. Furthermore, the effects of 2-ME on blood pressure and cardiovascular remodeling in the constricted aorta (CA) rat model and on isoproterenol-induced (ISO) cardiac hypertrophy and fibrosis were examined. 2-ME had no effects on Ang II-induced acute changes in blood pressure, renal hemodynamics, or glomerular filtration rate. Both 2-ME and 2-HE reduced hypertension, cardiac hypertrophy, proteinuria, and mesangial expansion induced by chronic Ang II infusions. In CA rats, 2-ME attenuated cardiac hypertrophy and fibrosis and reduced elevated blood pressure above the constriction. Notably, 2-ME reduced both pressure-dependent (above constriction) and pressure-independent (below constriction) vascular remodeling. 2-ME had no effects on ISO-induced renin release yet reduced ISO-induced cardiac hypertrophy and fibrosis. This study shows that 2-ME protects against cardiovascular and renal injury due to chronic activation of the renin–angiotensin system. This study reports for the first time that in vivo 2-ME reduces trophic (pressure-independent) effects of Ang II and related cardiac and vascular remodeling.
- 1 March 2019
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 73 (3) , 165-177
2-Methoxyestradiol Attenuates Angiotensin II-Induced Hypertension, Cardiovascular Remodeling, and Renal Injury
Estradiol may antagonize the adverse cardiovascular effects of angiotensin II (Ang II). We investigated the effects of 2-methoxyestradiol (2-ME), a nonestrogenic estradiol metabolite, on Ang II-induced cardiovascular and renal injury in male rats. First, we determined the effects of 2-ME on Ang II-induced acute changes in blood pressure, renal hemodynamics, and excretory function. Next, we investigated the effects of 2-ME and 2-hydroxyestardiol (2-HE) on hypertension and cardiovascular and renal injury induced by chronic infusion of Ang II. Furthermore, the effects of 2-ME on blood pressure and cardiovascular remodeling in the constricted aorta (CA) rat model and on isoproterenol-induced (ISO) cardiac hypertrophy and fibrosis were examined. 2-ME had no effects on Ang II-induced acute changes in blood pressure, renal hemodynamics, or glomerular filtration rate. Both 2-ME and 2-HE reduced hypertension, cardiac hypertrophy, proteinuria, and mesangial expansion induced by chronic Ang II infusions. In CA rats, 2-ME attenuated cardiac hypertrophy and fibrosis and reduced elevated blood pressure above the constriction. Notably, 2-ME reduced both pressure-dependent (above constriction) and pressure-independent (below constriction) vascular remodeling. 2-ME had no effects on ISO-induced renin release yet reduced ISO-induced cardiac hypertrophy and fibrosis. This study shows that 2-ME protects against cardiovascular and renal injury due to chronic activation of the renin–angiotensin system. This study reports for the first time that in vivo 2-ME reduces trophic (pressure-independent) effects of Ang II and related cardiac and vascular remodeling.
- 1 June 2018
- Published by Springer Nature in Reproductive Sciences
- Vol. 25 (6) , 950-957
HOXB4 Immunoreactivity in Endometrial Tissues From Women With or Without Endometriosis
Subscription and open access journals from SAGE Publishing, the world's leading independent academic publisher.
- 1 June 2018
- Published by Springer Nature in Reproductive Sciences
- Vol. 25 (6) , 950-957
HOXB4 Immunoreactivity in Endometrial Tissues From Women With or Without Endometriosis
Subscription and open access journals from SAGE Publishing, the world's leading independent academic publisher.
- 1 April 2018
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 71 (4) , 205-214
Captopril Attenuates Cardiovascular and Renal Disease in a Rat Model of Heart Failure With Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF), a prevalent form of heart failure, is frequently accompanied by the metabolic syndrome and kidney disease. Because current treatment options of HFpEF are limited, evaluation of therapies in experimental models of HFpEF with the metabolic syndrome and kidney disease is needed. In this study, we evaluated the effects of captopril, furosemide, and their combination in aged, obese ZSF1 rats, an animal model of HFpEF with the metabolic syndrome and chronic kidney disease as comorbidities. Captopril (100 mg/kg), furosemide (50 mg/kg), or their combination was administered orally to obese ZSF1 rats aged 20 to 44 weeks. Untreated ZSF1 rats served as controls. After 24 weeks of treatment, captopril significantly lowered systemic blood pressure and attenuated HFpEF as evidenced by significantly reduced left ventricular end diastolic pressures (10.5 ± 1.4 vs. 4.9 ± 1.3 mm Hg in Control vs. Captopril, respectively) and significantly lower left ventricular relaxation time constants (28.1 ± 2.9 vs. 18.3 ± 3.1 ms in Control vs. Captopril, respectively). The captopril-induced improvement in left ventricular function was associated with reduced cardiac hypertrophy, ischemia, necrosis, and vasculitis. Captopril also increased renal blood flow and glomerular filtration rate, reduced renal vascular resistance and proteinuria, and improved renal histology (ie, reduced renal hypertrophy, glomerulosclerosis, and tubular atrophy/dilation). Furosemide alone provided little benefit; moreover, furosemide did not augment the therapeutic benefits of captopril. This study suggests that chronic administration of captopril, but not furosemide, could be beneficial in patients with HFpEF, particularly in those with comorbidities such as obesity, diabetes, and dyslipidemias.
- 1 April 2018
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 71 (4) , 205-214
Captopril Attenuates Cardiovascular and Renal Disease in a Rat Model of Heart Failure With Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF), a prevalent form of heart failure, is frequently accompanied by the metabolic syndrome and kidney disease. Because current treatment options of HFpEF are limited, evaluation of therapies in experimental models of HFpEF with the metabolic syndrome and kidney disease is needed. In this study, we evaluated the effects of captopril, furosemide, and their combination in aged, obese ZSF1 rats, an animal model of HFpEF with the metabolic syndrome and chronic kidney disease as comorbidities. Captopril (100 mg/kg), furosemide (50 mg/kg), or their combination was administered orally to obese ZSF1 rats aged 20 to 44 weeks. Untreated ZSF1 rats served as controls. After 24 weeks of treatment, captopril significantly lowered systemic blood pressure and attenuated HFpEF as evidenced by significantly reduced left ventricular end diastolic pressures (10.5 ± 1.4 vs. 4.9 ± 1.3 mm Hg in Control vs. Captopril, respectively) and significantly lower left ventricular relaxation time constants (28.1 ± 2.9 vs. 18.3 ± 3.1 ms in Control vs. Captopril, respectively). The captopril-induced improvement in left ventricular function was associated with reduced cardiac hypertrophy, ischemia, necrosis, and vasculitis. Captopril also increased renal blood flow and glomerular filtration rate, reduced renal vascular resistance and proteinuria, and improved renal histology (ie, reduced renal hypertrophy, glomerulosclerosis, and tubular atrophy/dilation). Furosemide alone provided little benefit; moreover, furosemide did not augment the therapeutic benefits of captopril. This study suggests that chronic administration of captopril, but not furosemide, could be beneficial in patients with HFpEF, particularly in those with comorbidities such as obesity, diabetes, and dyslipidemias.
- 1 June 2016
- Published by Elsevier in Ultrasound in Medicine & Biology
- Vol. 42 (6) , 1330-1336
Sonographic Findings in Gouty Arthritis: Diagnostic Value and Association with Disease Duration
- 1 June 2016
- Published by Elsevier in Ultrasound in Medicine & Biology
- Vol. 42 (6) , 1330-1336
Sonographic Findings in Gouty Arthritis: Diagnostic Value and Association with Disease Duration
- 1 February 2016
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 356 (2) , 333-340
Dual A1/A2B Receptor Blockade Improves Cardiac and Renal Outcomes in a Rat Model of Heart Failure with Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) is prevalent and often accompanied by metabolic syndrome. Current treatment options are limited. Here, we test the hypothesis that combined A1/A2B adenosine receptor blockade is beneficial in obese ZSF1 rats, an animal model of HFpEF with metabolic syndrome. The combined A1/A2B receptor antagonist 3-[4-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)-1-bicyclo[2.2.2]octanyl]propanoic acid (BG9928) was administered orally (10 mg/kg/day) to obese ZSF1 rats (n = 10) for 24 weeks (from 20 to 44 weeks of age). Untreated ZSF1 rats (n = 9) served as controls. After 24 weeks of administration, BG9928 significantly lowered plasma triglycerides (in mg/dl: control group, 4351 ± 550; BG9928 group, 2900 ± 551) without adversely affecting plasma cholesterol or activating renin release. BG9928 significantly decreased 24-hour urinary glucose excretion (in mg/kg/day: control group, 823 ± 179; BG9928 group, 196 ± 80) and improved oral glucose tolerance, polydipsia, and polyuria. BG9928 significantly augmented left ventricular diastolic function in association with a reduction in cardiac vasculitis and cardiac necrosis. BG9928 significantly reduced 24-hour urinary protein excretion (in mg/kg/day: control group, 1702 ± 263; BG9928 group, 1076 ± 238), and this was associated with a reduction in focal segmental glomerulosclerosis, tubular atrophy, tubular dilation, and deposition of proteinaceous material in the tubules. These findings show that, in a model of HFpEF with metabolic syndrome, A1/A2B receptor inhibition improves hyperlipidemia, exerts antidiabetic actions, reduces HFpEF, improves cardiac histopathology, and affords renal protection. We conclude that chronic administration of combined A1/A2B receptor antagonists could be beneficial in patients with HFpEF, in particular those with comorbidities such as obesity, diabetes, and dyslipidemias.
- 1 February 2016
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 356 (2) , 333-340
Dual A1/A2B Receptor Blockade Improves Cardiac and Renal Outcomes in a Rat Model of Heart Failure with Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) is prevalent and often accompanied by metabolic syndrome. Current treatment options are limited. Here, we test the hypothesis that combined A1/A2B adenosine receptor blockade is beneficial in obese ZSF1 rats, an animal model of HFpEF with metabolic syndrome. The combined A1/A2B receptor antagonist 3-[4-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)-1-bicyclo[2.2.2]octanyl]propanoic acid (BG9928) was administered orally (10 mg/kg/day) to obese ZSF1 rats (n = 10) for 24 weeks (from 20 to 44 weeks of age). Untreated ZSF1 rats (n = 9) served as controls. After 24 weeks of administration, BG9928 significantly lowered plasma triglycerides (in mg/dl: control group, 4351 ± 550; BG9928 group, 2900 ± 551) without adversely affecting plasma cholesterol or activating renin release. BG9928 significantly decreased 24-hour urinary glucose excretion (in mg/kg/day: control group, 823 ± 179; BG9928 group, 196 ± 80) and improved oral glucose tolerance, polydipsia, and polyuria. BG9928 significantly augmented left ventricular diastolic function in association with a reduction in cardiac vasculitis and cardiac necrosis. BG9928 significantly reduced 24-hour urinary protein excretion (in mg/kg/day: control group, 1702 ± 263; BG9928 group, 1076 ± 238), and this was associated with a reduction in focal segmental glomerulosclerosis, tubular atrophy, tubular dilation, and deposition of proteinaceous material in the tubules. These findings show that, in a model of HFpEF with metabolic syndrome, A1/A2B receptor inhibition improves hyperlipidemia, exerts antidiabetic actions, reduces HFpEF, improves cardiac histopathology, and affords renal protection. We conclude that chronic administration of combined A1/A2B receptor antagonists could be beneficial in patients with HFpEF, in particular those with comorbidities such as obesity, diabetes, and dyslipidemias.
- 1 January 2016
- Published by Egyptian Knowledge Bank in Mansoura Journal of Forensic Medicine and Clinical Toxicology
- Vol. 24 (1) , 73-95
Spermatotoxic Effects of Aflatoxin B1 in a Sample of Sohag Population and in Rabbits
Aflatoxins (A-flavus-toxins) are the most studied group of mycotoxins. At smaller concentrations the Aflatoxins can affect male reproduction, namely spermatogenesis. The present study was designed to investigate the effect of Aflatoxin-B1 on male reproductive system by two ways: clinically on human beings and experimentally on rabbits. Human study was conducted on 100 males attending outpatients of Andrology Clinic of Sohag University Hospitals; 50 males had normal seminogram and 50 males had abnormal seminogram. Animal study was conducted on 45 adult NZW rabbit bucks. They were divided into three groups. Each group was divided to three subgroups; (negative control, positive control and treated rabbits). Treated subgroups received Aflatoxin B1 by i.p injection at 20 ∝ g/ kg/BW per day (subtoxic dose) for different durations (30 days, 48 days and 63 days). Human study showed significant increase in seminal plasma Aflatoxin-B1 level in the infertile group. The increased AFB1 level affected significantly semen parameters. Experimental results showed significant negative correlation between the seminal AFB1 level and sperm concentration, sperm viability and total sperm motility but showed significant positive correlation with abnormal sperm forms. Histopathological examination showed degeneration of seminifrous tubules. The tubules showed absence of mature sperms with appearance of uninucleated and multinucleated giant cells. Epididymal epithelium showed vaculation and degeneration. From the obtained results, it can be concluded that Aflatoxin B1 affect male reproductive system functionally and pathologically.
- 1 January 2016
- Published by Egyptian Knowledge Bank in Mansoura Journal of Forensic Medicine and Clinical Toxicology
- Vol. 24 (1) , 73-95
Spermatotoxic Effects of Aflatoxin B1 in a Sample of Sohag Population and in Rabbits
Aflatoxins (A-flavus-toxins) are the most studied group of mycotoxins. At smaller concentrations the Aflatoxins can affect male reproduction, namely spermatogenesis. The present study was designed to investigate the effect of Aflatoxin-B1 on male reproductive system by two ways: clinically on human beings and experimentally on rabbits. Human study was conducted on 100 males attending outpatients of Andrology Clinic of Sohag University Hospitals; 50 males had normal seminogram and 50 males had abnormal seminogram. Animal study was conducted on 45 adult NZW rabbit bucks. They were divided into three groups. Each group was divided to three subgroups; (negative control, positive control and treated rabbits). Treated subgroups received Aflatoxin B1 by i.p injection at 20 ∝ g/ kg/BW per day (subtoxic dose) for different durations (30 days, 48 days and 63 days). Human study showed significant increase in seminal plasma Aflatoxin-B1 level in the infertile group. The increased AFB1 level affected significantly semen parameters. Experimental results showed significant negative correlation between the seminal AFB1 level and sperm concentration, sperm viability and total sperm motility but showed significant positive correlation with abnormal sperm forms. Histopathological examination showed degeneration of seminifrous tubules. The tubules showed absence of mature sperms with appearance of uninucleated and multinucleated giant cells. Epididymal epithelium showed vaculation and degeneration. From the obtained results, it can be concluded that Aflatoxin B1 affect male reproductive system functionally and pathologically.
- 1 January 2015
- Published by Elsevier in Gastroenterology
- Vol. 148 (1) , 181-191.e17
Genomic Instability Causes HGF Gene Activation in Colon Cancer Cells, Promoting Their Resistance to Necroptosis
- 1 January 2015
- Published by Elsevier in Gastroenterology
- Vol. 148 (1) , 181-191.e17
Genomic Instability Causes HGF Gene Activation in Colon Cancer Cells, Promoting Their Resistance to Necroptosis
- Open Access
- 1 December 2014
- Published by Springer Nature in Journal of the Egyptian National Cancer Institute
- Vol. 26 (4) , 211-217
E-cadherin and CD10 expression in atypical hyperplastic and malignant endometrial lesions
Background: Loss of E-cadherin is a critical step for development and progression of malignant tumors. CD10; a marker of non-neoplastic and neoplastic endometrial stroma, is associated with aggressiveness of many epithelial malignancies. Aims: To evaluate expression and correlation of E-cadherin and CD10 in endometrial lesions and their possible role in differentiating atypical endometrial hyperplasia from endometrial carcinoma. The association of E-cadherin and CD10 expression with clinico-pathological parameters of endometrial carcinoma was also investigated. Materials and methods: Fifty four cases including 28 endometrial carcinomas; 19 endometrial hyperplasia and 7 cases of normal endometrial changes were enrolled for this study. The expression of E-cadherin and CD10 was evaluated by immunohistochemistry using the streptavidin-biotin technique. Results: There was a strong association between malignant change of endometrial glands and mem-brano-cytoplasmic localization of E-cadherin (p < 0.001). Expression of E-cadherin but not CD10 was significantly higher in endometrial carcinomas compared to atypical endometrial hyperplasia (p < 0.01). Expression of E-cadherin was not associated with CD10 expression in different endometrial lesions. High grade tumors expressed low levels of both E-cadherin (p < 0.01) and CD10 (p < 0.05) and serous endometrial carcinoma had low E-cadherin and CD10 expression compared to endometrioid carcinoma (p < 0.01 and < 0.05, respectively). Expression of both molecules showed no association with depth of tumor invasion or FIGO stage. Tumors with lower E-cadherin or CD10 expression had higher rates of vascular tumor emboli (p < 0.01 and < 0.07, respectively). Conclusions: Although expression of E-cadherin and CD10 in endometrial lesions was not correlated, reduced expression of both molecules could be critical for progression of endometrial carcinoma. (C) 2014 Production and hosting by Elsevier B.V. on behalf of National Cancer Institute, Cairo University.
- 1 December 2014
- Published by Springer Nature in Journal of the Egyptian National Cancer Institute
- Vol. 26 (4) , 211-217
Open AccessE-cadherin and CD10 expression in atypical hyperplastic and malignant endometrial lesions
Background: Loss of E-cadherin is a critical step for development and progression of malignant tumors. CD10; a marker of non-neoplastic and neoplastic endometrial stroma, is associated with aggressiveness of many epithelial malignancies. Aims: To evaluate expression and correlation of E-cadherin and CD10 in endometrial lesions and their possible role in differentiating atypical endometrial hyperplasia from endometrial carcinoma. The association of E-cadherin and CD10 expression with clinico-pathological parameters of endometrial carcinoma was also investigated. Materials and methods: Fifty four cases including 28 endometrial carcinomas; 19 endometrial hyperplasia and 7 cases of normal endometrial changes were enrolled for this study. The expression of E-cadherin and CD10 was evaluated by immunohistochemistry using the streptavidin-biotin technique. Results: There was a strong association between malignant change of endometrial glands and mem-brano-cytoplasmic localization of E-cadherin (p < 0.001). Expression of E-cadherin but not CD10 was significantly higher in endometrial carcinomas compared to atypical endometrial hyperplasia (p < 0.01). Expression of E-cadherin was not associated with CD10 expression in different endometrial lesions. High grade tumors expressed low levels of both E-cadherin (p < 0.01) and CD10 (p < 0.05) and serous endometrial carcinoma had low E-cadherin and CD10 expression compared to endometrioid carcinoma (p < 0.01 and < 0.05, respectively). Expression of both molecules showed no association with depth of tumor invasion or FIGO stage. Tumors with lower E-cadherin or CD10 expression had higher rates of vascular tumor emboli (p < 0.01 and < 0.07, respectively). Conclusions: Although expression of E-cadherin and CD10 in endometrial lesions was not correlated, reduced expression of both molecules could be critical for progression of endometrial carcinoma. (C) 2014 Production and hosting by Elsevier B.V. on behalf of National Cancer Institute, Cairo University.
- 1 May 2014
- Published by Elsevier in European Journal of Cancer
- Vol. 50, e59
P0173 Use of PTEN, PCNA, and β-catenin to differentiate between endometrial hyperplasia and endometrial adenocarcinoma
- 1 May 2014
- Published by Elsevier in European Journal of Cancer
- Vol. 50, e59
P0173 Use of PTEN, PCNA, and β-catenin to differentiate between endometrial hyperplasia and endometrial adenocarcinoma